A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

Who May Qualify: - Able to comprehend and willing to sign an willing to sign a consent form form (ICF) and to abide by the study restrictions; - Males or females, of any race; - Body mass index (BMI) between 18.0 and 40.0 kg/m2, inclusive; - Male subjects are not allowed to donate sperm, and female subjects are not allowed to donate eggs from the time the ICF is signed until at least 3 months after the last follow-up. Who Should NOT Join This Trial: - Any history or evidence of abnormal bleeding or coagulopathy; or evidence of prolonged or unexplained, clinically significant bleeding, or frequent unexplained bruising or thrombosis; or history of spontaneous bleeding; - Evidence of active or suspected cancer within 3 years prior to screening (non-melanoma skin cancer, localized prostate cancer treated with curative intent, or other in situ carcinoma that does not require systemic therapy and is considered cured for at least 1 years is allowed); - Acute febrile illness within 7 days prior to dose administration or evidence of active infection; - Any major surgery within 3 months prior to screening or plan to have any major surgery during the study; - History of clinically significant hypersensitivity, intolerance, or allergy to any oligonucleotide or GalNAc as determined by the investigator; - Fasting TG≥ 500 mg/dL (5.6 mmol/L) during screening; - Receipt of an investigational drug within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study; - Have previously completed or withdrawn from this study or any other study investigating SRSD216 and have previously received SRSD216. Always talk to your doctor about whether this trial is right for you.